Repositioning Gains Momentum in Biopharma Partnerships

June 13, 2013Media coverage

Article by Marie Powers in BioWorld; Monday, June 10, 2013 Article summary: Chronic fatigue syndrome (CFS) has been at the center of a vortex of controversy since the FDA handed down a complete response letter on the Toll-like receptor 3 modulator Ampligen (rintatolimod) from Hemispherx Bioscience Inc. – the only drug in development for CFS … Read More

Partnering for Cures – Biovista presentation

December 3, 2012Events, Multimedia

Presentation- CFIDS Association of America / Biovista View the joint presentation by Biovista President Dr. Aris Persidis and CFIDS’ Scientific Director, Dr. Suzanne Vernon at the 2012 Partnering for Cures conference. The collaboration between the CFIDS Association of America and Biovista leverages the accumulated knowledgebase for chronic fatigue syndrome (CFS) and Biovista’s state-of-the-art approaches to … Read More

World Drug Repositioning Congress

November 28, 2012Events

Join us at the upcoming World Drug Repositioning Congress, 4 – 5 December 2012, 20 F Street NW Conference Center, Washington, DC, US Biovista’s Aris Persidis is presenting a talk titled Very large scale systematic drug repositioning as a business and technology driver Topics covered include: Big data technologies enabling the deployment of systemic drug … Read More

Partnering for Cures meeting

November 22, 2012Events

  Join us at the upcoming Partnering for Cures meeting, November 28-30, 2012 in NY City. Biovista will be co-presenting with the CFIDS Association of America its repositioning work on Chronic Fatigue Syndrome within the event’s prestigious Innovator Presentations session. The session focuses on organizations “engaged in innovative, cross-sector collaborations aimed at reducing the time … Read More

The Path of Least Resistance: Repositioned Drugs Surpass New Brands

October 24, 2012Media coverage

Article by PharmExec’s Clark Herman on the 505(b)(2) pathway for drug approval … Aris Persidis, president and co-founder of Biovista, a company focused on the 505(b)(2), adds, “In addition, the first to file patent regulations that will take effect in the US next year are making companies realize that they may be susceptible to competitors … Read More